|1.||Zhao, Shiwen: 1 article (04/2012)|
|2.||Li, Shao: 1 article (04/2012)|
|3.||Kosmala, Wojciech: 1 article (04/2004)|
|4.||Spring, Adam: 1 article (04/2004)|
|5.||Hancock, J: 1 article (01/2004)|
|6.||Monaghan, M J: 1 article (01/2004)|
|7.||Nihoyannopoulos, P: 1 article (01/2004)|
|8.||Calachanis, M: 1 article (01/2004)|
|9.||Evdoridis, C: 1 article (01/2004)|
|10.||Prasan, A: 1 article (01/2004)|
|1.||Coronary Artery Disease (Coronary Atherosclerosis)
11/01/1995 - "In this study, closed-loop arbutamine administration was effective and safe in the detection of coronary artery disease for both heart rate slope regimens."
11/01/1995 - "Arbutamine echocardiography is an effective and safe pharmacologic stress test technique for diagnosing or excluding the presence of coronary artery disease. "
11/01/1995 - "Safety and efficacy of computerized closed-loop delivery of arbutamine: a new pharmacologic myocardial stress modality for the assessment of coronary artery disease. "
09/01/1998 - "This study examined the hemodynamic effects of arbutamine, a synthetic catecholamine, in 12 patients with and 7 patients without coronary artery disease. "
03/15/1997 - "Thirty-seven patients were entered into the study (35 arbutamine and exercise, 1 arbutamine only, 1 exercise only), of which 30 had angiographic evidence of coronary artery disease (> or = 50% lumen diameter narrowing). "
|2.||Myocardial Ischemia (Ischemic Heart Diseases)
11/15/1996 - "Although exercise is the preferred method of stress for patients who are able to exercise adequately, arbutamine is at least as sensitive as exercise for the diagnosis of myocardial ischemia, and appears to be a safe and effective alternative to exercise testing in patients unable to exercise adequately."
03/15/1997 - "Comparison of arbutamine and exercise echocardiography in diagnosing myocardial ischemia."
03/01/1996 - "The efficacy and safety of arbutamine were also evaluated in a canine model of myocardial ischemia obtained by partially occluding the left anterior descending coronary artery. "
11/01/1995 - "The ability of arbutamine stress to induce myocardial ischemia, detectable by echocardiography, was comparable to that for exercise."
11/01/1995 - "Among those patients who had both stress test results, the incidence of inducing myocardial ischemia (new or worsening wall motion abnormalities) was 79% (95% confidence interval [CI] 69% to 86%, n = 98) for arbutamine and 77% (95% CI 67% to 85%, n = 98) for exercise echocardiography. "
11/15/1996 - "The primary purpose of the trial was to compare the efficacy of arbutamine with symptom-limited exercise in provoking clinical (angina), electrocardiographic (> or = 0.1 mV ST depression) and echocardiographic (induced wall motion abnormality) evidence of transient stress-induced ischemia. "
03/15/1997 - "This study compared the sensitivity of arbutamine with symptom-limited exercise to induce echocardiographic signs of ischemia. "
03/15/1997 - "In conclusion, the sensitivity of arbutamine to induce echocardiographic signs of ischemia was similar to that of exercise despite a lower rate-pressure product. "
03/01/1997 - "The system uses a novel catecholamine, arbutamine, which is infused intravenously to increase heart rate (HR) and cardiac contractility in order to evoke signs of ischemia. "
11/15/1996 - "No serious adverse events, either cardiac or noncardiac, were associated with arbutamine, and no patient had prolonged ischemia. "
12/01/2001 - "This study sought to evaluate the safety and efficacy of arbutamine echocardiography in identifying contractile reserve and predicting functional improvement early after acute myocardial infarction (AMI). "
12/01/2001 - "Identification of viable myocardium early after acute myocardial infarction using closed-loop arbutamine echocardiography: comparison with positron emission tomography."
|5.||Coronary Stenosis (Coronary Artery Stenosis)
05/01/2002 - "In this study using a canine model, we compared the effects of arbutamine stress on myocardial blood flow, myocardial MIBI uptake, and systolic thickening in the presence of a coronary artery stenosis. "
05/01/2002 - "In the presence of coronary stenoses that abolished regional flow reserve, myocardial uptake of MIBI, compared with (201)Tl, significantly underestimated the arbutamine-induced flow heterogeneity. "
05/01/2002 - "Arbutamine was infused (0.5-250 ng/kg/min) in 8 open-chest dogs with critical coronary stenoses that abolished flow reserve. "
05/01/2002 - "Arbutamine stress perfusion imaging in dogs with critical coronary artery stenoses: (99m)Tc-sestamibi versus (201)Tl."
|4.||Technetium (Technetium 99m)
|9.||contrast agent BR1